Free Drugs & Biotech case summaries from Justia.
If you are unable to see this message, click here to view it in a web browser. | | Drugs & Biotech January 8, 2021 |
|
|
Click here to remove Verdict from subsequent Justia newsletter(s). | New on Verdict Legal Analysis and Commentary | One More for the Road: Why Congress Must Impeach Donald Trump (Again) | DEAN FALVY | | Dean Falvy, a lecturer at the University of Washington School of Law in Seattle, makes the case for impeaching Donald Trump again, after the failed insurrection of January 6. Falvy describes three possible ways to disempower Trump from undermining democracy in our nation and explains why immediate impeachment by the House and removal by the Senate is the most appropriate course of action. | Read More |
|
Drugs & Biotech Opinions | Knight v. Boehringer Ingelheim Pharmaceuticals, Inc. | Court: US Court of Appeals for the Fourth Circuit Docket: 19-1636 Opinion Date: January 6, 2021 Judge: Quattlebaum Areas of Law: Constitutional Law, Drugs & Biotech | After Boehringer developed a drug called Pradaxa to help reduce the risk of stroke, the FDA approved the drug and its label. Betty Knight suffered complications from taking the drug and eventually died. Betty's children filed suit against Boehringer asserting a variety of state-law claims alleging Boehringer failed to adequately warn about the risks associated with taking Pradaxa. Boehringer argued that federal law preempted the claims, the district court agreed with plaintiffs, and then the jury returned a mixed verdict. Boehringer appealed, claiming that plaintiffs' fraud claim based on the physician label was preempted. The Fourth Circuit reversed the district court's order denying Boehringer's post-trial motion for judgment as a matter of law. The court held that there is no bright-line, one-size-fits-all line marking the moment when an analysis reveals new information. A careful review of the record is needed to determine whether a conclusion has been reached. Applying careful review here, the court concluded that Boehringer did not have "newly acquired information" regarding an optimal Pradaxa blood concentration level which would have warranted a unilateral change to the physician label. Therefore, the state-law fraud claim is preempted. | |
|
About Justia Opinion Summaries | Justia Weekly Opinion Summaries is a free service, with 63 different newsletters, each covering a different practice area. | Justia also provides 68 daily jurisdictional newsletters, covering every federal appellate court and the highest courts of all US states. | All daily and weekly Justia newsletters are free. Subscribe or modify your newsletter subscription preferences at daily.justia.com. | You may freely redistribute this email in whole. | About Justia | Justia is an online platform that provides the community with open access to the law, legal information, and lawyers. |
|
|